Moderna and Merck Advance mRNA Cancer Vaccine Trial in First-Line Lung Cancer

Moderna announced an update on their ongoing clinical study testing an mRNA-based cancer vaccine in advanced lung cancer. The Phase 2 study, designated INTerpath-013, is a randomized, double-blind, placebo-controlled trial evaluating whether adding Moderna's V940 to standard lung cancer therapy improves survival in advanced disease.

The trial targets patients with metastatic squamous non-small cell lung cancer who have not received prior treatment. V940, also known as mRNA-4157 or Intismeran Autogene, is given as an injection to help the immune system better recognize and attack each patient's tumor. It is tested in combination with Merck's checkpoint inhibitor Keytruda (pembrolizumab) and standard chemotherapy drugs carboplatin plus paclitaxel or nab-paclitaxel, with a matching placebo used in the control arm.

The study is interventional and randomized, meaning patients are assigned by chance to V940 or placebo on top of the same backbone of Keytruda and chemotherapy. It uses a parallel-arm design with triple blinding, so patients, doctors, and outcome assessors do not know who receives V940, and the main goal is to see whether this treatment approach improves outcomes compared with standard care alone.

The trial is listed as recruiting, with study setup originally submitted on 24 October 2025, marking the formal start of the program from a regulatory and site-activation standpoint. The latest update on 18 February 2026 signals active management of the protocol, but primary and final completion dates are not yet posted, underscoring that key efficacy readouts and top-line data remain several years away.

The recruiting status and early-stage nature of the trial mean near-term revenue impact is limited, and sentiment will remain tied to broader mRNA execution and other pipeline news until data emerge. The competitive backdrop includes other immunotherapy combinations and cancer vaccines from large pharma and biotech peers.

Therapeutic vaccines are advancing in oncology, with mRNA cancer vaccines enabling the body to produce tumor-specific antigens that trigger immune responses. Their flexibility allows development across multiple cancer types, with numerous clinical trials exploring safety, effectiveness, and broader therapeutic applications. Cancer vaccines are increasingly combined with immunotherapies such as checkpoint inhibitors to enhance treatment outcomes. Clinical studies indicate improved immune activation, reduced recurrence risk, and stronger therapeutic responses compared with single-modality cancer treatment approaches.

Unlike classic prophylactic vaccines, which are designed to generate long-lasting immune memory against external pathogens, therapeutic vaccines are intended to modulate the existing immune response in a precise and targeted manner. The goal is to correct dysfunction or strengthen immune control when it is lacking. These approaches are often tailored to an individual's biological profile, reflecting advances in immunology and technological platforms, such as multi-epitope mRNA vaccines, neoantigen-based vaccines, and formulations combined with immunotherapy.

Currently, research is focused on teaching the immune system to accurately recognize tumor cells and attack them selectively and sustainably over time. These strategies aim to reduce the tumor burden, delay disease progression, prevent relapses, and improve survival, particularly in individuals with minimal residual disease after surgery. Such strategies include individualized neoantigen vaccines, multiepitope mRNA constructs, synthetic peptides, and dendritic cells engineered to stimulate CD4-positive and CD8-positive T-cell responses.

Melanoma has emerged as the principal translational model because of its high mutational burden and sensitivity to immune checkpoint blockade and has become the primary model for translating these advances into clinical benefits. A 2025 study published in Cell evaluating the NeoVax and NeoVaxMI platforms demonstrated broad, polyclonal, mutation-specific T cell responses against tumor mutations. The results showed significant improvements by optimizing antigen selection, dosing, and formulation.

According to a 2025 review of next-generation mRNA vaccines for melanoma, vaccine performance depends primarily on antigen selection and optimization of multiple features of the RNA construct itself, including codon tuning, secondary structure, and chemical modifications intended to enhance stability while limiting nonspecific immune activation. Structural elements, such as the 5′ and 3′ untranslated regions, Cap1 type cap, and poly(A) tail length, are also critical, as they directly influence mRNA half-life and protein expression levels.

These molecular advances have been accompanied by parallel progress in the field of drug delivery. Lipid nanoparticles remain the dominant platform, although formulations have been refined to improve tissue and cellular targeting. In addition, hybrid delivery approaches that combine lipid nanoparticles with tumor cell membranes or extracellular vesicles are under investigation, enabling some antigens to be displayed on the particle surface, while others are encoded intracellularly.